US FDA Opinions Vary On AI’s Black Box Issues. Will Uncertainty Follow?

 
• By Derrick Gingery

Chief Medical Officer Hilary Marston says a black box model could be a problem for reviewers, after CDER and CBER officials said unexplainable AI models could be acceptable but transparency is important.

Transparency is important with an AI black box, the FDA said. (Shutterstock)

More from AI

More from Pathways & Standards